Drug Trial Radar · NCT02665286
Orphenadrine and Methocarbamol for LBP
Last checked: Nov 20, 2026Latest source record: Jun 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
Mar 2016
Primary completion
Apr 2017
Study completion May 2017
Sponsor
- Lead sponsor
- Montefiore Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 27, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Low back pain is a common cause of visit to emergency department. It is not clear if skeletal muscle relaxants are of benefit for patients with acute low back pain. This is a randomized study to determine if skeletal muscle relaxants, when combined with naproxen, improve outcomes more than naproxen alone
Conditions
- Low Back Pain
Interventions
OrphenadrineDrug
Orphenadrine 100mg PO BID x 7 days
MethocarbamolDrug
Methocarbamol 750mg 1-2 tabs po TID x 7 days
NaproxenDrug
Naproxen 500mg PO BID x 7 days
PlaceboDrug
1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Functional Impairment as Measured on the Roland Morris Disability QuestionnaireTime frame: 1 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Montefiore Medical Center
The Bronx, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.